Alexandria Forbes

President, Chief Executive Officer & Director at Meiragtx Holdings Plc

Alexandria Forbes

Alexandria Forbes

President, Chief Executive Officer & Director at Meiragtx Holdings Plc

Overview
Career Highlights

Meiragtx Holdings Plc

RelSci Relationships

82

Number of Boards

4

Birthday

1965

Age

56

Relationships
RelSci Relationships are individuals Alexandria Forbes likely has professional access to. A relationship does not necessarily indicate a personal connection.

President, Chief Executive Officer & Director at Kadmon Holdings, Inc.

Relationship likelihood: Strong

Founder at Evrys Bio LLC

Relationship likelihood: Strong

Executive Vice President & Chief Financial Officer at Kadmon Holdings, Inc.

Relationship likelihood: Strong

Chief Operating & Financial Officer at Meiragtx Holdings Plc

Relationship likelihood: Strong

President & Chief Executive Officer at Kadmon Pharmaceuticals LLC

Relationship likelihood: Strong

Chief Development Officer at Meiragtx Holdings Plc

Relationship likelihood: Strong

Chief Investment Officer & Co-Founder at Cohen Private Ventures LLC

Relationship likelihood: Strong

Chief Executive Officer at The Bridge, Inc.

Relationship likelihood: Strong

President & Director at American Dermatological Association, Inc.

Relationship likelihood: Strong

Vice Chairman at Forbes Family Trust

Relationship likelihood: Strong

Paths to Alexandria Forbes
Potential Connections via
Relationship Science
You
Alexandria Forbes
President, Chief Executive Officer & Director at Meiragtx Holdings Plc
Education

The University of Cambridge (informally known as Cambridge University or Cambridge) is a public research university located in Cambridge, United Kingdom. It is the second-oldest university in the English-speaking world (after the University of Oxford), and the seventh-oldest in the world.

Oxford is a collegiate university, consisting of the central University and colleges. The central University is composed of academic departments and research centres, administrative departments, libraries and museums. The 38 colleges are self-governing and financially independent institutions, which are related to the central University in a federal system. There are also six permanent private halls, which were founded by different Christian denominations and which still retain their Christian character.

Career History
Managing Director
Prior - 2008

Sivik invests almost exclusively in US growth stocks in the healthcare technology and services sector without regard to capitalization size. They use a combination top-down, bottom-up approach to find companies with new drugs or technologies and sector dominance or competitive advantages. SIVIK maintains a high turnover

Partner
Prior

Meadowvale Partners Capital Management manages a multi-manager hedge fund. Portfolios are designed to provide clients' overall portfolios with diversification, low volatility and attractive risk-adjusted returns.

Senior Vice President-Commercial Operations
2013 - 2018

Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY.

Boards & Committees
Director
2015 - Current

MeiraGTx Ltd. engages in the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The company was founded on March 20, 1991 and is headquartered in London, the United Kingdom.

President, Chief Executive Officer & Director
2015 - Current

MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. It focuses on inherited retinal diseases, neurodegenerative diseases, and severe forms of xerostomia. It operates through the following geographical segments: United States, Ireland, Netherlands, and United Kingdom. Its pipeline includes AAV CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1 and AAV-UPF1. The company was founded on March 20, 2015 and is headquartered in New York, NY.

Member, Board of Managers
2010 - Current

Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY.

Political Donations
$1,000
2011

Senator from Rhode Island

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Alexandria Forbes. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Alexandria Forbes's profile does not indicate a business or promotional relationship of any kind between RelSci and Alexandria Forbes.